PSEG (PEG) Q3 2026 Earnings Call Transcript

PSEG reported Q3 2026 non-GAAP operating earnings of $1.15 per share, up from $1.13 a year earlier, while GAAP net income declined to $0.76 per share from $1.24. Management reaffirmed full-year 2026 operating earnings guidance of $4.28–$4.40 per share and its 6%–8% earnings-growth target through 2030. Nuclear output was 8.2 TWh at a 95.5% capacity factor in Q3; the company also cited $24 billion–$28 billion of planned investment through 2030, higher financing costs, and ongoing PJM resource adequacy and regulatory uncertainty.

Analysis

The key valuation tension is not the growth target itself, but whether New Jersey permits timely recovery of the investment needed to deliver it. A constructive year-end filing could lower perceived regulatory lag; an affordability-led framework that defers recovery would instead leave PEG funding rate-base expansion with debt while depreciation and refinancing costs rise. The filing’s mechanism and allowed returns matter more than its headline revenue request.

Power-market read-through is also more nuanced than a generic PJM scarcity trade. The widening PECO-to-West hub discount weakens the case for extrapolating Western hub prices into PEG’s earnings, while its hedge positioning limits near-term sensitivity. Longer term, persistent regional congestion could support transmission investment, but that creates value for PEG only if projects are awarded and recovery is authorized. Large-load nuclear contracts could reduce merchant-price exposure and monetize upgrades; until signed, they are optionality, not a forecastable earnings leg.

Near term (days), guidance reaffirmation is supportive but offers little new information. Over 1–3 months, the New Jersey filing and February 2027 outlook are the clearest catalysts. Over 6–18 months, financing costs, regulatory recovery and contracted load additions will determine whether planned rate-base growth converts into per-share growth. Main falsifiers: a filing that does not close the recovery gap, a lower 2027 growth outlook, or further basis widening that erodes realized power prices despite hedges.

Key Decisions for Investors

• Do not chase the call-driven move. Consider a relative long PEG versus XLU only after reviewing the New Jersey filing: require clear, timely recovery mechanics and no deterioration in the 6%–8% growth framework. Reassess if the February outlook resets that range or the filing leaves material investment recovery unresolved.
• Treat any nuclear scarcity premium as conditional. Track executed large-load contracts, contract tenor and pricing, and whether upgrades are included; do not capitalize management’s ongoing discussions as earnings until terms are disclosed.
• Monitor PECO-versus-West basis and PEG’s hedge disclosure rather than using PJM Western hub prices as a proxy for earnings. A further widening alongside weaker realized nuclear prices would invalidate the near-term insulation thesis.
• For credit and equity risk, watch financing costs against regulatory recovery: the no-equity funding plan is more credible if cash generation and rate mechanisms keep pace with capex. Rising debt costs without timely recovery would pressure the growth multiple.